Assessing factor consumption and bleeding outcomes of prophylaxis with 3 commonly prescribed factor IX products for hemophilia B: A retrospective patient medical record analysis in the United States
In this retrospective study, rIX-FP prophylaxis was associated with lower FIX consumption and potentially improved protection against bleeds compared with prophylactic treatment with rFIXFc and rFIX.
Authors
- Douglass Alan Drelich (ORCID: https://orcid.org/0009-0004-7388-2013)
- Mindy Simpson (ORCID: https://orcid.org/0000-0001-5925-0117)
- Songkai Yan (ORCID: https://orcid.org/0000-0002-1677-3839)
- Gbenga A Kayode (ORCID: https://orcid.org/0000-0001-6313-010X)
- Miguel A. Escobar (ORCID: https://orcid.org/0000-0002-2944-0240)
- Xiang Zhang (ORCID: https://orcid.org/0000-0002-7543-8352)
- Ying Yang (ORCID: https://orcid.org/0000-0001-7079-5927)
- Mariama Jabati
Institutions
- Rush University Medical Center (US)
- Engineering Associates (United States) (US)
- CSL (United States) (US)
- The University of Texas Health Science Center (US)
Publication Details
- Journal
- Journal of Managed Care & Specialty Pharmacy
- Published
- 2025-11-14
- DOI
- https://doi.org/10.18553/jmcp.2025.25148
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00